Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus XENOVIEW.
SODIUM IODIDE I 123 vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical